uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences. (Akut- och internmedicin)
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
Show others and affiliations
2002 (English)In: American Journal of Hypertension, ISSN 0895-7061, Vol. 15, no 5, 389-93 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Our aim was to determine whether the aldosterone synthase (CYP11B2) -344 C/T polymorphism was associated with the blood pressure (BP)-lowering response to antihypertensive treatment. METHODS: Patients with mild-to-moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind study to receive treatment with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan (n = 43), or the beta1-adrenergic receptor blocker atenolol (n = 43). The aldosterone synthase (CYP11B2) -344 C/T polymorphism was analyzed using solid-phase minisequencing and related to BP reduction after 3 months treatment. Serum aldosterone levels were measured. RESULTS: After 3 months treatment the mean reductions in BP were similar for both treatment groups. When assessing the systolic BP reduction in the irbesartan group, patients with the TT variant had a more pronounced reduction (-21 +/- 19 SD mm Hg, n = 17) than both the TC (-14 +/- 18 mm Hg, n= 18) and CC (0 +/- 17 mm Hg, n = 8) genotypes (P = .04). There was no association between this polymorphism and the diastolic BP response. The -344 C/T polymorphism was not associated with the BP response to atenolol. Nor was it related to the baseline serum aldosterone level. CONCLUSIONS: The aldosterone synthase -344 C/T polymorphism was related to the BP-lowering response in hypertensive patients treated with the AT1-receptor antagonist irbesartan.

Place, publisher, year, edition, pages
2002. Vol. 15, no 5, 389-93 p.
Keyword [en]
Adrenergic beta-Antagonists/*therapeutic use, Aldosterone/blood, Aldosterone Synthase/*genetics, Antihypertensive Agents/*therapeutic use, Atenolol/*therapeutic use, Base Sequence/genetics, Biphenyl Compounds/*therapeutic use, Blood Pressure, Comparative Study, Cytosine, Double-Blind Method, Female, Humans, Hypertension/blood/*drug therapy/*genetics/physiopathology, Hypertrophy; Left Ventricular/drug therapy, Male, Middle Aged, Polymorphism; Genetic, Receptor; Angiotensin; Type 1, Receptors; Angiotensin/antagonists & inhibitors, Research Support; Non-U.S. Gov't, Tetrazoles/*therapeutic use, Thymine, Treatment Outcome
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-73165DOI: 10.1016/S0895-7061(02)02256-2PubMedID: 12022239OAI: oai:DiVA.org:uu-73165DiVA: diva2:101076
Available from: 2005-06-01 Created: 2005-06-01Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12022239&dopt=Citation

Search in DiVA

By author/editor
Kurland, LisaMelhus, HåkanKarlsson, JuliaLind, Lars
By organisation
Department of Medical Sciences
In the same journal
American Journal of Hypertension
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 100 hits
ReferencesLink to record
Permanent link

Direct link